ABSTRACT
Background Vaccination campaigns were rolled out primarily to limit the impact of COVID-19 on severe health outcomes, including mortality.
Aim We aimed to estimate the number of averted deaths by COVID-19 vaccination in the Belgian population aged 65 years and older, between January 2021 and January 2023.
Methods Nationwide data on COVID-19 infections, vaccine administrations and all-cause mortality were individually linked. We estimated Vaccine Effectiveness against COVID-19 mortality (VE) among persons having received a vaccine dose in the last 6 months, using a Cox proportional hazards model adjusted for age, sex, time since vaccination, previous infection, underlying health conditions, province and income. COVID-19 death was defined as a person with a laboratory-confirmed SARS-CoV-2 infection who died within a specified interval. Based on obtained VE estimates, vaccine coverage and national COVID-19 mortality data, we estimated the number of averted deaths.
Results We estimated VE (0-59 days after vaccination) for 65-79 year and ≥80 year-olds respectively, at 81.9% (78.1%-85.1%) and 74.7% (71.2%-77.7%) during Alpha, at 90.5% (88.8%-91.9%) and 91.4% (90.4%- 92.4%) during Delta and at 84.0% (81.8%-85.9%) and 74.5% (72.4%-76.5%) during Omicron period. Among the Belgian population aged 65 years and older, we estimated 12,806 deaths averted (11,633- 13,982), representing a 54% reduction (51%-56%) in the expected deaths (without vaccination). During the Delta period COVID-19 deaths were reduced by 68%, during Omicron by 54% and during Alpha by 31%.
Discussion Vaccinating against COVID-19 reduced deaths by 54% among the Belgian population aged 65 years and older, underscoring the importance of COVID-19 vaccines in reducing mortality.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by the Belgian Federal and Regional Authorities through funding for the LINK-VACC project. The funding source had no role in the study design, analysis, interpretation, or decision to submit the paper. The Regional Authorities contributed in collection of the data and in writing of the report.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Data linkage and collection within the data-warehouse has been approved by the information security committee. The study was conducted in accordance with the Declaration of Helsinki. Ethical approval was granted for the gathering of data from hospitalised patients by the Committee for Medical Ethics from the Ghent University Hospital (reference number BC-07507) and authorisation for possible individual data linkage using the national register number from the Information Security Committee (ISC) Social Security and Health (reference number IVC/KSZG/20/384). Linkage of hospitalised patient data to vaccination, and testing within the LINK-VACC project was approved by the Medical Ethics Committee UZ Brussels/VUB on 3 February 2021 (reference number 2020/523), and authorisation from the ISC Social Security and Health (reference number IVC/KSZG/21/034). Informed consent was waived based on art. 6 and 9 of the GDPR. The collection is allowed based on general interest (art. 6 GDPR) and regarding article 9 section 2 of the GDPR: processing is necessary for reasons of public interest in the area of public health, such as protecting against serious cross-border threats to health, or ensuring high standards of quality and safety of health care and of medicinal products or medical devices, on the basis of Union or Member State law which provides for suitable and specific measures to safeguard the rights and freedoms of the data subject, in particular, professional secrecy.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos